Lilly study links Zepbound to lower costs in adults over 55
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq drags on Wall St as AI slowdown fears hammer Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% as attacks halt Saudi pipeline
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
August 26, 2026 6:45 AM EDTFirst-of-its-kind study shows sustained Zepbound use in older adults with obesity lowers costs, reinforcing the potential value of the Medicare GLP-1 Bridge program
Individuals treated with Zepbound had lower rates of hospital admissions and emergency department visits
INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from a real-world... More
